Extinction and Pharmacotherapies for Drug Addiction (R03)

The summary for the Extinction and Pharmacotherapies for Drug Addiction (R03) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Extinction and Pharmacotherapies for Drug Addiction (R03): -Purpose. The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research on the mechanisms underlying extinction in order to guide the development of interventions for enhancing extinction of drug-seeking behavior. It is expected that research supported under this FOA will ultimately be used to guide and implement combined behavioral and pharmacological/molecular interventions for the treatment of drug abuse relapse. -Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the R03 grant mechanism and runs in parallel with a FOA of identical scientific scope, RFA-DA-07-010, that solicits applications under the Research Project Grant (R01) grant mechanism and will be issued at a later date. For the purpose of this FOA, the R03 mechanism is intended only for pilot, feasibility studies or small, self-contained studies that can be completed in a short period of time. -Funds Available and Anticipated Number of Awards. It is anticipated that $2 million in total costs will be awarded to a total of 6-8 applications for this announcement and its companion R01 FOA (RFA-DA-07-010).

Federal Grant Title:	Extinction and Pharmacotherapies for Drug Addiction (R03)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health Education
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-07-011
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	No deadline provided
Original Application Deadline:	Feb 27, 2007
Posted Date:	Nov 03, 2006
Creation Date:	Nov 03, 2006
Archive Date:	Mar 29, 2007
Total Program Funding:	$2,000,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Public and State controlled institutions of higher education State governments Public housing authorities/Indian housing authorities Independent school districts Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) For profit organizations other than small businesses City or township governments Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) County governments
Additional Information on Eligibility: Foreign institutions are not eligible to apply. Eligible agencies of the Federal Government can apply. Faith-based or community-based organizations can apply.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...; • Optimizing Behavioral Sleep Interventions for Adolescents and Young Adults (R34 Clinical T...; • Global Infectious Disease Research Training Program (D43 Clinical Trial Optional); • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...